Elevar Therapeutics: NDA resubmitted to FDA for rivoceranib + camrelizumab as first-line systemic treatment for unresectable or metastatic hepatocellular carcinoma

Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd., announced the FDA accepted the resubmission of a new drug application (NDA) for its investigational drug rivoceranib, an oral VEGF-TKI, in combination with camrelizumab, a PD-1 inhibitor, as a first-line systemic treatment for unresectable or metastatic hepatocellular carcinoma (uHCC)